ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

On December 21, 2017, the Registrant delivered a $1,800,000 secured convertible promissory note (the “Note”) to Eagle Equities, LLC (“Eagle”) and received $1,800,000 from Eagle. The Note is convertible into our common stock at 65% of market as determined under the Note, bears interest at 10% per annum and is secured to a security agreement (the “Security Agreement”) by a third priority lien against certain of our assets. In connection with the issuance of the Note, Eagle was granted a two year warrant (the “Warrant”) to acquire 1,800,000 of our shares at $0.25 per share. The Warrant contains a cashless exercise feature.

The foregoing is only a brief summary of the agreements referred to hereon, which are exhibits hereto, for a full understanding of their terms and conditions of those documents, the reader is referred to such documents.

Item 9.01 Financial Statements and Exhibits.

ENDONOVO THERAPEUTICS, INC. Exhibit
EX-10.1 2 ex10-1.htm   EXHIBIT 10.1   SECURITIES PURCHASE AGREEMENT   This SECURITIES PURCHASE AGREEMENT (the “Agreement”),…
To view the full exhibit click here

About ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV)

Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.